The intermediate conductance calcium-activated potassium channel IKCa1 1 (also known as IK1, KCa4, SK4, KCNN4, and the "Gardos channel") plays an important role in the physiology of lymphocytes, erythrocytes, and intestinal and airway epithelial cells (1) (2) (3) (4) . IKCa1 channels are voltage-independent, and their activation is steeply sensitive to rises in intracellular Ca 2ϩ , calcium sensitivity being conferred by calmodulin tightly complexed to the C terminus of the channel (5). Pharmacologically, IKCa1 channels are distinguished from SK Ca (SKCa1-3) channels by their sensitivity to clotrimazole and charybdotoxin and by their insensitivity to apamin.
In mitogen-activated human lymphocytes, IKCa1 regulates membrane potential and calcium signaling, and selective inhibitors of IKCa1 suppress lymphocyte proliferation and cytokine secretion by attenuating Ca 2ϩ influx (4, 6 -9) . In red blood cells, IKCa1 participates in volume control. Erythrocyte dehydration in sickle cell disease can be attributed partly to excessive K ϩ loss through IKCa1 channels that are activated by a rise in intracellular Ca 2ϩ during sickling (10) . Clotrimazole and ICA-15451, two potent triarylmethane (TRAM) blockers of this channel, are in clinical trials for the treatment of sickle cell disease (11, 12) . In intestinal and airway epithelium cells, basolateral expression of the IKCa1 channel modulates apical water and Cl Ϫ secretion (13, 14) , and blockade of this channel by clotrimazole has been reported to ameliorate secretory diarrhea (15) . However, the therapeutic usefulness of clotrimazole is seriously limited by its nanomolar affinity for cytochrome P450-dependent enzymes, especially CYP3A4 (the major xenobiotic metabolizing enzyme in human liver), which leads to a high incidence of side effects (11, 16) .
Starting with clotrimazole as a template, we recently designed and synthesized TRAM analogs that block IKCa1 potently and specifically without inhibiting P450-dependent enzymes (8) . The most potent of these, TRAM-34, blocks IKCa1 with a K d of 20 nM and exhibits exquisite selectivity for the channel. Related TRAMs containing tetrazole (TRAM-84) or acetonitrile (TRAM-39) in place of the pyrazole are also selective and potent inhibitors of IKCa1. Although applied externally, the TRAMs are readily membrane-permeant because of their high lipophilicity (logP value 3.5-5.0) and may interact with a site on the inner face of the channel. Furthermore, a membrane-impermeant clotrimazole analog has been reported previously to block the native IK Ca channel in erythrocytes only when applied to the cytoplasmic surface, suggesting an internal binding site (17) . In the present study, we have used molecular chimeras and mutagenesis to identify the channel residues that interact with the TRAM inhibitors.
EXPERIMENTAL PROCEDURES
Reagents-Clotrimazole, econazole, ketoconazole, nifedipine, and TEA were purchased from Sigma. Charybdotoxin (ChTX) was from Bachem (King of Prussia, PA). TRAM-34 ([1-(2-chlorophenyl)diphenyl) methyl]-1H-pyrazole), TRAM-3 ((2-chlorophenyl)diphenylmethanol), and TRAM-39 (2-(2-chlorophenyl)-2,2-diphenylacetonitrile) were synthesized as described previously (8) . TRAM-30 was prepared by refluxing clotrimazole (2.00 g, 5.81 mmol) with an excess of methyl iodide in butanone for 36 h. The reaction mixture was evaporated to dryness. On addition of petroleum ether to the resulting oily residue and intensive cooling and scratching, the material began to solidify and was then washed thoroughly with acetone and petroleum ether (mp: 139°C; 1H * This work was supported by National Institutes of Health Grants MH59222 (to K. G. C.) and NS14609 (to M. D. C.) and an American Heart Association fellowship grant 9920014Y (to H. W.). The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact. Clones and Mutants-The cloning of human IKCa1 (GenBank TM accession number AF033021) and human SKCa3 containing 19 polyglutamines in the N terminus (GenBank TM accession numbers AF031815 and AJ251016) have been reported previously (2, 18, 19) . Both channel genes were subcloned into the pEGFP-C1 vector (CLON-TECH) in frame with GFP. Mutant IKCa1 channels were generated by either one-or two-step polymerase chain reaction. Polymerase chain reaction products were digested with HindIII/BbrPI and cloned into HindIII/BbrPI-cut GFP-IKCa1. For SKCa3 mutations, KpnI and a Cterminal-introduced BamHI site were used. All clones were verified by sequencing. The DNA for transfection was prepared with the Qiagen (Valencia, CA) mini-prep kit.
Electrophysiological Analysis-COS-7 cells were cultured in Dulbecco's modified Eagle's medium containing 10% fetal calf serum, 2 mM glutamine, 1 mM Na ϩ pyruvate, 100 units/ml penicillin, and 100 g/ml streptomycin. The cells were transiently transfected with GFP-tagged wild-type or mutant IKCa1 and SKCa3 cDNAs using FuGene™ 6 (Roche) according to manufacturer protocol. Cells were trypsinized 16 -72 h after transfection, plated onto polylysine-coated coverslips, and used within the next 4 h. Whole-cell patch clamp recordings (EPC-9, HEKA Elektronik) were made at a holding potential of Ϫ80 mV with a pipette solution containing 145 mM K ϩ aspartate, 2 mM MgCl 2, 10 mM HEPES, 10 mM K 2 EGTA, and 8.5 mM CaCl 2 (1 M free [Ca 2ϩ ]) , pH 7.2, 290 -310 mosM. To reduce currents from the native chloride channels in COS-7, Na ϩ aspartate Ringer was used as an external solution containing 160 mM Na ϩ aspartate, 4.5 mM KCl, 2 mM CaCl 2 , 1 mM MgCl 2 , and 5 mM HEPES, pH 7.4, 290 -310 mosM. Currents were elicited by 200-ms voltage ramps from Ϫ120 to 40 mV applied every 10 s, and the reduction of slope conductance at Ϫ80 mV by drug was taken as a measure of channel block. The recordings in Fig. 1 were done on excised inside-out patches with the external solution described above as pipette solution. K ϩ aspartate solutions containing 1 M and 50 nM free [Ca 2ϩ ] were applied to the cytoplasmic side of the patch.
RESULTS

The Binding Site for TRAMs Is Situated on the Cytoplasmic
Surface of IKCa1-IKCa1 channels are potently blocked by clotrimazole and related TRAMs with a Hill coefficient of unity. These highly lipophilic compounds readily cross the plasma membrane and block the channel with a slow onset. An earlier study (17) that used a membrane-impermeant clotrimazole analog on the native IK Ca channel in erythrocytes reported a drug-binding site on the cytoplasmic surface of the channel. To confirm this prediction on the cloned channel we generated a membrane-impermeant quaternary TRAM (TRAM-30) and evaluated its ability to block IKCa1 when added from the outside (in the whole-cell configuration) or the intracellular side in inside-outside patches. As a control we studied clotrimazole (logP ϭ 3.5), which is freely membrane-permeant.
Currents (10 -200 pA) in inside-out patches from IKCa1-expressing COS-7 cells excised into 1 M Ca 2ϩ disappeared when the Ca 2ϩ concentration was reduced to 50 nM and were restored after the re-addition of 1 M Ca 2ϩ (Fig. 1A) . This Ca 2ϩ -activated current was completely and rapidly blocked by 1 M clotrimazole (Fig. 1, A and B) , and its K ϩ selectivity was confirmed by the shift in reversal potential when the Na ϩ aspartate pipette solution was replaced by K ϩ aspartate (Fig.  1C) . These IKCa1 currents were also reversibly blocked by the membrane-impermeant quaternary compound, TRAM-30 (Fig.  1, D and E) with a K d of 700 nM (Fig. 1F, ⌬) , which was almost ineffective (K d ϭ 350 M, OE) when applied to the external surface of the channel in the whole-cell configuration. In contrast, the membrane-permeant clotrimazole blocked the channel with equal potency when applied to either side of the membrane (Fig. 1F, f and Ⅺ) . The 10-fold lower potency of TRAM-30 compared with clotrimazole is caused by the bulk of the additional methyl group on the imidazole ring, consistent with the published pharmacophore of the TRAMs (8). These results suggest that TRAMs interact with a site on the intracellular surface of the channel.
The TRAM-binding Site Is Located in the S5-P-S6
Region-To localize the region on the channel to which the TRAMs bind, we generated a chimera between IKCa1 and the phylogenetically related TRAM-insensitive small conductance SKCa3 channel ( Fig. 2A) . In whole-cell recordings, IKCa1 currents were potently blocked by externally applied TRAM-34 ( Fig. 2A, left) , whereas SKCa3 was insensitive ( Fig. 2A, middle) . A chimera containing the SKCa3 S5-P-S6 region in the IKCa1 body was insensitive to 1 M TRAM-34 ( Fig. 2A, right) . Together with the data obtained in inside-out experiments (see above), these results suggest that the TRAM-binding site is situated on the cytoplasmic side of the S5-P-S6 region of IKCa1.
An alignment of the IKCa1 and SKCa3 amino acid sequences through this region reveals 45 differences (Fig. 2B) . To define the residues involved we replaced IKCa1 residues with the corresponding ones from SKCa3. Mutations were made in the cytoplasmic half of S5, the intracellular portion of the P-loop and the entire S6 segment, and as a control we also mutated residue 239 that had been shown previously to be involved in ChTX binding (20) . Mutations involving Thr 250 (P245S ϩ T250S; or T250S) or Val 275 (V275A ϩC276G; or V275A) abolished sensitivity to TRAM-34 and clotrimazole, whereas all other mutants showed unchanged TRAM-34 sensitivity (Fig.  2B , Table I ). The V272I mutant could not be investigated because it was nonfunctional. The T250S and V275A mutants were studied in more detail. 275 Selectively Abolish TRAM Sensitivity-The T250S mutant produced a K ϩ -selective current equally sensitive to block by ChTX (K d ϭ 5 Ϯ 1 nM), TEA (K d ϭ 20 Ϯ 4 mM), and nifedipine (K d ϭ 5 Ϯ 1 M) as the wild-type IKCa1 channel (4, 8, 20) , whereas it was completely insensitive to TRAM-34 (Fig. 3, A-D) . Similar results were obtained with the V275A mutant (Fig. 3, E-H) . Thus, these two point mutations selectively abolished TRAM-34 sensitivity completely abolished TRAM sensitivity. The C276G point mutant was not generated, because Cys 276 faces away from the pore in a published model of IKCa1 (20) . Others: these mutants did not alter TRAM sensitivity significantly with the exception of the G259H ϩ 261Y ϩ W262C mutant, which reduced TRAM sensitivity 6-fold. These residues are buried in the IKCa1 model, and the small change in TRAM sensitivity resulting from their substitution with SKCa3 residues may be caused by an indirect effect via alteration of the shape of the protein.
Mutations of Thr 250 and Val
without altering other pharmacological properties of the channel or its K ϩ selectivity, indicating that the overall conformation of these mutant channels had not been grossly perturbed. It also shows that the TRAM-binding site is distinct from those of ChTX, TEA, and nifedipine.
The TRAM pharmacophore consists of two parts, a triphenyl moiety and either a small heterocycle or another -electronrich substituent such as an acetonitrile or hydroxyl group. To identify the part of the molecule that interacts with the channel, we first examined four TRAMs that contain the triphenyl moiety but different substituents, TRAM-34 (pyrazole), TRAM-39 (acetonitrile), TRAM-3 (hydroxyl), and clotrimazole (imidazole). All four compounds were inactive on the T250S and V275A mutant channels (Fig. 4) . In contrast, two azole inhibitors of IKCa1 (econazole and ketoconazole) containing an imidazole moiety such as clotrimazole but lacking the triphenyl group blocked both mutant channels as effectively as the wildtype channel (Figs. 3H and 4) . Collectively, these results suggest that the triphenyl moiety interacts with Thr 250 and Val 275 . Thr  250 and  Val  275 constitute the TRAM-binding site, introduction of these residues into the SKCa3 channel should confer sensitivity to the TRAMs. The SKCa3-S507TϩA532V mutant produced a K ϩ -selective channel (Fig. 5A ) that was blocked by apamin with a potency roughly equal to the wild-type SKCa3 channel (Fig. 5B) . Unlike SKCa3, which was relatively insensitive to TRAM-34 (K d ϭ 28 M), the S507TϩA532V-SKCa3 mutant was substantially blocked by 1 and 5 M TRAM-34 (K d ϭ 680 Ϯ 70 nM, Fig. 5, C and D) .
Introducing TRAM Sensitivity into SKCa3-If
A IKCa1 pore (20) based on the KcsA crystal structure (Fig. 6) . Both residues line a large water-filled cavity that lies just below the narrow selectivity filter of the channel, which is formed by the conserved GYG motif. If this cavity in IKCa1 is as wide as the 10-Å cavity in KcsA, it should easily accommodate clotrimazole and TRAM-34, both of which have dimensions of 9.5 ϫ 9.5 ϫ 8.6 Å. An AM-1-optimized structure of TRAM-34 drawn to scale is shown in Fig. 6 next to the channel model. A highly lipophilic membrane-permeant compound like TRAM-34 (logP ϭ 4.0) could easily reach the internal cavity either by traversing the ion conduction pathway from the inside or through crevices and tunnels in the protein similar to those recently described in sodium channels (21) .
DISCUSSION
Using a combination of electrophysiology and mutagenesis we have defined the TRAM-binding site on IKCa1. Our data suggest that the binding site is located on the cytoplasmic side of the S5-P-S6 region of the channel. First, a membrane-impermeant analog blocks the channel with 500-fold greater potency when added from the inside versus the outside, and second, introduction of the S5-P-S6 region of the TRAM-resistant SKCa3 into IKCa1 renders the channel insensitive to these compounds. Single and multiple replacements of IKCa1 residues in the S5-P-S6 region with the corresponding residues in SKCa3 identified Thr 250 in the P-region and Val 275 in S6 as being critical for TRAM binding. Based on our IKCa1 model (20), both these residues lie in close proximity to each other in the water-filled cavity below the ion selectivity filter. The introduction of these two residues into SKCa3 made this channel TRAM-sensitive. Given the tetrameric nature of K ϩ channels, the TRAM-binding site could involve , although they share little sequence similarity with IKCa1 in the residues neighboring the threonine and valine (22) . The threonine and valine residues in these channels may be oriented differently from Thr 250 and Val 275 in IKCa1, resulting in a less than optimal interaction with the phenyl rings of TRAM-34. Differences in the shape of the internal cavities of these channels compared with IKCa1 may also contribute to TRAM insensitivity. Bulky residues in the vicinity of the threonine or valine in these channels may also sterically interfere with their ability to interact with TRAMs.
In an earlier study, we proposed that the TRAM-binding site had dimensions of roughly 9.5 ϫ 9.5 ϫ 8.6 Å based on structure-activity relationships of the TRAMs; introduction of bulky substituents on the triphenyl moiety or on the heterocycle abolished affinity (8) . Consistent with this earlier report, our heuristic model suggests that TRAM-34 could fit snugly into the internal cavity just below the selectivity filter with each of the phenyl rings locked in place by interactions with Thr 250 and Val 275 from three of the four IKCa1 subunits. We propose that the -electron cloud of the phenyl rings of TRAM-34 form hydrophobic interactions with the positively polarized hydrogen atoms of the methyl group of Thr 250 . The conservative substitution of serine in place of Thr 250 abolishes TRAM sensitivity, possibly because serine lacks the side chain methyl group of threonine. Val 275 could also form a hydrophobic interaction with the phenyl rings. This interaction must be size-dependent, because the introduction of the smaller alanine (88 Å 3 ) in place of the valine (140 Å 3 ) abolishes TRAM sensitivity.
Although each hydrophobic interaction in itself is weak, taken together they may well account for the 20 nM K d value of TRAM-34. Our model also predicts that the heterocyclic moiety could project upwards into the selectivity filter and occlude the ion conduction pathway.
